Psychiatric Medications Linked to Elevated ALS Risk in Swedish Study

Researchers at Sweden's Karolinska Institute have found that people taking certain psychiatric medications show a measurably higher risk of developing amyotrophic lateral sclerosis, the most common form of motor neurone disease. The discovery, drawn from a comparison of over 1,000 ALS patients diagnosed between 2015 and 2023 against more than 5,000 matched controls without the disease, adds a new layer to an already complex picture of how psychiatric and neurological conditions may intersect.

The three drug classes showed the clearest associations: anxiolytics—medications for anxiety—were linked to a 34 percent increase in ALS risk, while sedatives and hypnotics showed a 21 percent increase, and antidepressants a 26 percent increase. These percentages sound substantial in isolation, but they must be weighed against the fact that ALS itself remains rare, affecting roughly 9 in 100,000 people in the United States. The absolute risk to any individual taking these medications remains very small. Still, the finding matters because millions of people worldwide take antidepressants and anti-anxiety drugs to manage common mental health conditions, and understanding even modest risk factors could reshape how clinicians think about long-term treatment.

What makes the Swedish data particularly noteworthy is not just the initial diagnosis risk but what happened afterward. People who had taken psychiatric medications before their ALS diagnosis showed a faster rate of disease decline and faced an elevated risk of earlier death once the illness took hold. ALS itself offers no cure; it progressively destroys the nervous system, leading to paralysis and eventually respiratory failure. The prospect of accelerated deterioration adds weight to the findings, even as researchers emphasize that the data cannot yet prove the medications directly cause the increased risk.

The team accounted for genetic and environmental factors in their analysis, a methodological step that strengthens confidence in the connection between medication use and ALS risk. Yet causation remains elusive. It is entirely possible that the psychiatric conditions themselves—depression, anxiety, sleep disorders—are the underlying driver, and that both the need for medication and the vulnerability to ALS stem from some shared biological vulnerability. The medications may be a marker of that vulnerability rather than its cause. Susannah Tye, a neuroscientist at the University of Queensland who was not involved in the research, cautioned that while the study adds to evidence that psychiatric conditions may elevate neurodegeneration risk, the implication that the medications themselves are responsible should be treated with caution.

Previous research has already established that people with psychiatric disorders face higher ALS risk overall, independent of medication. This new work provides granular detail to that broader pattern. It suggests that the relationship between mental health and motor neurone disease is neither simple nor one-directional, but rather woven into the fabric of how the nervous system ages and breaks down. For clinicians prescribing antidepressants or anti-anxiety medications, the findings do not suggest abandonment of these drugs—their benefits for mental health are well-established and their use is widespread—but rather a reminder that long-term neurological outcomes deserve attention in treatment planning.

The research, published in JAMA Network Open, represents one more thread in the slow accumulation of knowledge about ALS risk factors. Scientists are gradually mapping the terrain of what makes some people vulnerable to this devastating disease, work that may eventually point toward prevention or effective treatment. For now, the Swedish study stands as evidence that the connections between psychiatric health and neurodegeneration run deeper than previously understood, and that unraveling them may require looking beyond the medications themselves to the conditions they treat.